| Substitute Form PTO-1449 (Modified) | U.S. Department of Commerce Patent and Trademark Office | Attorney's Docket No. 07917-190001 | Application No. 10/789,247 |
|---|---|---|---|
| **Information Disclosure Statement by Applicant** (Use several sheets if necessary) | | Applicant Lu et al. | |
| (37 CFR §1.98(b)) | | Filing Date February 27, 2004 | Group Art Unit 1616 |

**U.S. Patent Documents**

| Examiner Initial | Desig. ID | Document Number | Publication Date | Patentee | Class | Subclass | Filing Date If Appropriate |
|---|---|---|---|---|---|---|---|
| MS | A1 | 5,552,143 | Sept. 3, 1996 | Plotkin et al. | | | |
| MS | A2 | 5,591,439 | Jan. 7, 1997 | Plotkin et al. | | | |
| MS | A3 | 5,720,957 | Feb. 24, 1998 | Jones et al. | | | |
| MS | A4 | 5,728,578 | Mar. 17, 1998 | Jahn et al. | | | |
| MS | A5 | 5,800,981 | Sept. 1, 1998 | Bruggeman et al. | | | |
| MS | A6 | 5,846,733 | Dec. 8, 1998 | Jahn et al. | | | |
| MS | A7 | 6,448,389 | Sep. 10, 2002 | Gonczol et al. | | | |
| | A8 | | | | | | |

**Foreign Patent Documents or Published Foreign Patent Applications**

| Examiner Initial | Desig. ID | Document Number | Publication Date | Country or Patent Office | Class | Subclass | Translation Yes | Translation No |
|---|---|---|---|---|---|---|---|---|
| MS | B1 | EP 0 389 286 B1 | 26/09/1990 | Europe | | | | |
| MS | B2 | EP 0 252 531 B | 02/12/1992 | Europe | | | X (abstract) | |
| MS | B3 | WO 97/40165 | 30/10/1997 | WIPO | | | | |
| MS | B4 | EP 0 236 145 | 09/09/1987 | Europe | | | | |
| MS | B5 | WO 01/72782 | 04/10/2001 | WIPO | | | | |
| MS | B6 | WO 02/34769 | 02/05/2002 | WIPO | | | | |
| | B7 | | | | | | | |

**Other Documents (include Author, Title, Date, and Place of Publication)**

| Examiner Initial | Desig. ID | Document |
|---|---|---|
| MS | C1 | Adler et al., "A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne)," J. Infect. Dis. 180(3):843-6 (1999) |
| MS | C2 | Berencsi et al., "A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects," J. Infect. Dis. 183(8):1171-9 (2001) |
| MS | C3 | Britt and Alford, "Cytomegalovirus," Fields Virology, 3d Ed., Chapter 77:2493-2523 (1996) |
| MS | C4 | Cull et al., "Coimmunisation with type I IFN genes enhances protective immunity against cytomegalovirus and myocarditis in gB DNA-vaccinated mice," Gene Ther. 9(20):1369-78 (2002) |

| Examiner Signature | Date Considered |
|---|---|
| /Magdalene Sgagias/ | 12/19/2006 |

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| Substitute Form PTO-1449 (Modified) | U.S. Department of Commerce Patent and Trademark Office | Attorney's Docket No. 07917-190001 | Application No. 10/789,247 |
|---|---|---|---|
| **Information Disclosure Statement by Applicant** (Use several sheets if necessary) (37 CFR §1.98(b)) | | Applicant Lu et al. | |
| | | Filing Date February 27, 2004 | Group Art Unit 1616 |

| Other Documents (include Author, Title, Date, and Place of Publication) | | |
|---|---|---|
| Examiner Initial | Desig. ID | Document |
| MS | C5 | Endresz et al., "Induction of human cytomegalovirus (HCMV)-glycoprotein B (gB)-specific neutralizing antibody and phosphoprotein 65 (pp65)-specific cytotoxic T lymphocyte responses by naked DNA immunization," Vaccine 17:50-58 (1999) |
| MS | C6 | Endresz et al., "Optimization of DNA immunization against human cytomegalovirus," Vaccine 19:3972-80 (2001) |
| MS | C7 | La Rosa et al., "Preclinical development of an adjuvant-free peptide vaccine with activity against CMV pp65 in HLA transgenic mice," Blood 100(10):3681-3689 (2002) |
| MS | C8 | Lu et al., "Antigen Engineering in DNA Immunization," Methods in Molecular Medicine 29:355-74 (2000) |
| MS | C9 | Mach et al., "Complex formation by human cytomegalovirus glycoproteins M (gpUL100) and N (gpUL73)," J. Virol. 74(24):11881-92 (2000) |
| MS | C10 | Morello et al., "Development of a vaccine against murine cytomegalovirus (MCMV), consisting of plasmid DNA and formalin-inactivated MCMV, that provides long-term, complete protection against viral replication," J. Virol. 76(10):4822-35 (2002) |
| MS | C11 | Temperton, "DNA vaccines against cytomegalovirus: current progress," Intl. J. Antimicrobial Agents 19:169-72 (2002) |
| MS | C12 | Oh et al., "Nasal absorption and biodistribution of plasmid DNA: an alternative route of DNA vaccine delivery," Vaccine 19(31):4519-25 (2001) |
| MS | C13 | S.A. Plotkin, "Vaccination against cytomegalovirus," Arch. Virol. 17:121-34 (2001) |
| MS | C14 | Scholl et al., "Prokaryotic expression of immunogenic polypeptides of the large phosphoprotein (pp150) of human cytomegalovirus," J. Gen. Virol. 69 (Pt 6):1195-204 (1988) |
| MS | C15 | Spaete et al., "Coexpression of Truncated Human Cytomegalovirus gH with the UL115 Gene Product or the Truncated Human Fibroblast Growth Factor Receptor Results in Transport of gH to the Cell Surface," Virology 193(2):853-61 (1993) |
| MS | C16 | Walker et al., "Characterization of Human Cytomegalovirus Strains by Analysis of Short Tandem Repeat Polymorphisms," J. Clin. Microbio. 39:2219-26 (2001) |
| | C17 | |

| Examiner Signature | Date Considered |
|---|---|
| /Magdalene Sgagias/ | 12/19/2006 |

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.